Q2 net product revenues surged 74% year-over-year to $1.2 billion, led by AMVUTTRA's strong first-line growth and robust U.S. demand. 2026 revenue guidance was lowered by $200 million at midpoint due to normalized second-line demand, but long-term growth targets remain supported by a large untreate…
Q2 net product revenues surged 74% year-over-year to $1.2 billion, led by AMVUTTRA's strong first-line growth and robust U.S. demand. 2026 revenue guidance was lowered by $200 million at midpoint due to normalized second-line demand, but long-term growth targets remain supported by a large untreated patient base and favorable market dynamics.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
